MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today received written notification from the NASDAQ Stock Market that the Company is no longer in compliance with the NASDAQ Listing Rules since MiMedx has not yet filed its Form 10-K for the year ended December 31, 2017. NASDAQ Listing Rule 5250(c)(1) requires NASDAQ-listed companies to timely file all periodic reports. As required, within 60 days the Company intends to submit a plan to regain compliance, and NASDAQ can grant an exception for MiMedx to remain listed for up to 180 calendar days from the Form 10-K's due date, or until August 28, 2018, if the plan is accepted. The NASDAQ's notice has no immediate effect on the listing of the Company's common stock.

About MiMedx 

MiMedx® is a leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. "Innovations in Regenerative Medicine" is the framework behind the Company's mission to give physicians products and tissues to help the body heal itself. The Company processes the human placental tissue utilizing its proprietary PURION® Process methodology, among other processes, to produce safe and effective allografts by employing aseptic processing techniques in addition to terminal sterilization. MiMedx has supplied over 1 million allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare. For additional information, please visit www.mimedx.com.